Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma

被引:0
作者
Sato, Sho [1 ]
Shintani, Daisuke [1 ]
Kaneda, Yuki [2 ]
Nakamura, Ryuichi [2 ]
Katoh, Tomomi [3 ]
Yano, Mitsutake [3 ]
Hanaoka, Mieko [1 ]
Yagishita, Shigehiro [4 ,5 ]
Yasuda, Masanori [3 ]
Nagata, Motoko [2 ]
Hasegawa, Kosei [1 ]
机构
[1] Saitama Med Univ, Dept Gynecol Oncol, Int Med Ctr, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Daiichi Sankyo Co Ltd, Translat Sci Dept 1, Shinagawa, Tokyo 1408710, Japan
[3] Saitama Med Univ, Int Med Ctr, Dept Pathol, Hidaka, Saitama 3501298, Japan
[4] Natl Canc Ctr, Div Mol Pharmacol, Res Inst, Tsukiji, Tokyo, Japan
[5] Natl Canc Ctr, Res Inst, Dept Pharmacol & Therapeut, Tsukiji, Tokyo, Japan
关键词
Ovarian cancer; HER3; IHC; Ovarian mucinous carcinoma; Ovarian clear cell carcinoma; Prognosis; ERBB RECEPTORS; HER3; OVEREXPRESSION; PACLITAXEL; SURVIVAL;
D O I
10.1007/s10147-024-02658-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundHuman epidermal growth factor receptor 3 (HER3), a tyrosine kinase belonging to the HER family, is a known target for cancer therapy; recently, an anti-HER3 antibody-drug conjugate (ADC) is developing. To understand HER3 expression in epithelial ovarian cancer (EOC), this study was conducted.MethodsWe investigated the expression of HER3 in 202 patients with EOC using immunohistochemistry (IHC), and the association between HER3 expression, clinicopathological features, prognosis, and treatment timing.ResultsOf all the cases, 55.4% had a HER3 IHC score >= 1 + . In particular, 78.0% of the patients with clear cell carcinoma (CCC) and 87.9% of the patients with mucinous carcinoma (MC) had a HER3 IHC score >= 1 + . Regarding clinicopathological features, early disease stage, feasibility of primary debulking surgery, no residual tumor, and low CA125 levels were more frequently observed in patients with a HER3 IHC score >= 1 + . Furthermore, a HER3 no-expression showed a significant association with a relatively short progression-free survival (PFS). And, for patients with mucinous carcinoma, those with a HER3 IHC score >= 1 + had poorer PFS and overall survival than those with a HER3 no-expression (no statistically significant difference). In addition, we analyzed HER3 expression at primary tumor and recurrence tumor in same patients. Thus, we observed the HER3 IHC score tended to change from 0 to >= 1 + in recurrence cases compared with primary cases.ConclusionsThese observations suggested that patients with MC, CCC and recurrence of all histological type may potentially benefit from future clinical trials of HER3-directed therapies.
引用
收藏
页码:805 / 813
页数:9
相关论文
共 34 条
[1]   Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors [J].
Aliyuda, Fine ;
Moschetta, Michele ;
Ghose, Aruni ;
Rallis, Kathrine Sofia ;
Sheriff, Matin ;
Sanchez, Elisabet ;
Rassy, Elie ;
Boussios, Stergios .
CURRENT CANCER DRUG TARGETS, 2023, 23 (06) :433-446
[2]   Targeting the PI3K Pathway in Gynecologic Malignancies [J].
Avila, Monica ;
Grinsfelder, Michaela Onstad ;
Pham, Melissa ;
Westin, Shannon N. .
CURRENT ONCOLOGY REPORTS, 2022, 24 (12) :1669-1676
[3]   Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells [J].
Bezler, Martin ;
Hengstler, Jan G. ;
Ullrich, Axel .
MOLECULAR ONCOLOGY, 2012, 6 (05) :516-529
[4]  
Chung YW, 2019, J GYNECOL ONCOL, V30
[5]  
Cîrstea AE, 2017, ROM J MORPHOL EMBRYO, V58, P1269
[6]   Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function [J].
Garrett, Joan T. ;
Sutton, Cammie R. ;
Kuba, Maria Gabriela ;
Cook, Rebecca S. ;
Arteaga, Carlos L. .
CLINICAL CANCER RESEARCH, 2013, 19 (03) :610-619
[7]   A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization [J].
Hashimoto, Yuuri ;
Koyama, Kumiko ;
Kamai, Yasuki ;
Hirotani, Kenji ;
Ogitani, Yusuke ;
Zembutsu, Akiko ;
Abe, Manabu ;
Kaneda, Yuki ;
Maeda, Naoyuki ;
Shiose, Yoshinobu ;
Iguchi, Takuma ;
Ishizaka, Tomomichi ;
Karibe, Tsuyoshi ;
Hayakawa, Ichiro ;
Morita, Koji ;
Nakada, Takashi ;
Nomura, Taisei ;
Wakita, Kenichi ;
Kagari, Takashi ;
Abe, Yuki ;
Murakami, Masato ;
Ueno, Suguru ;
Agatsuma, Toshinori .
CLINICAL CANCER RESEARCH, 2019, 25 (23) :7151-7161
[8]   The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation [J].
Holbro, T ;
Beerli, RR ;
Maurer, F ;
Koziczak, M ;
Barbas, CF ;
Hynes, NE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) :8933-8938
[9]   ErbB receptors and signaling pathways in cancer [J].
Hynes, Nancy E. ;
MacDonald, Gwen .
CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (02) :177-184
[10]   ERBB receptors and cancer: The complexity of targeted inhibitors [J].
Hynes, NE ;
Lane, HA .
NATURE REVIEWS CANCER, 2005, 5 (05) :341-354